Kamada .(US:KMDA) Globenewswire·2025-08-13 11:00Core Viewpoint - Kamada Ltd. reported strong financial results for the second quarter and first half of 2025, with significant revenue growth and increased adjusted EBITDA, leading to an upward revision of its annual guidance for both adjusted EBITDA and total revenues [2][4][9]. Financial Performance - Total revenues for the first half of 2025 were $88.8 million, an 11% increase year-over-year, with second-quarter revenues at $44.8 million, up 5% from $42.5 million in the same quarter of 2024 [4][5][11]. - Adjusted EBITDA for the first half of 2025 was $22.5 million, reflecting a 35% increase year-over-year, with a margin of 25% on revenues; second-quarter adjusted EBITDA was $10.9 million, up 20% year-over-year [4][11]. - Net income for the first half of 2025 was $11.3 million, or $0.19 per diluted share, a 67% increase compared to $6.8 million, or $0.12 per diluted share, in the first half of 2024 [11][20]. Operational Highlights - The company received FDA approval for its plasma collection center in Houston, Texas, which has an annual collection capacity of approximately 50,000 liters of plasma and is expected to contribute $8 million to $10 million in annual revenue at full capacity [2][12][17]. - Kamada continues to focus on expanding its plasma collection operations and is ramping up collection at its three Texas-based centers [2][12]. Strategic Outlook - Based on the strong performance in the first half of 2025, Kamada has increased its annual adjusted EBITDA guidance to a range of $40 million to $44 million and reiterated its full-year revenue guidance of $178 million to $182 million [2][9]. - The company is committed to investing in strategic growth pillars, including organic growth, business development, and M&A opportunities, to enhance its portfolio of marketed products [2][15][17].